Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy

Guang-Yi Sun†, Hao Jing†, Shu-Lian Wang*, Yong-Wen Song, Jing Jin, Hui Fang, Yue-Ping Liu, Hua Ren, Yu Tang, Xu-Ran Zhao, Yu-Chun Song, Si-Ye Chen, Zhuan-Bo Yang, Bo Chen, Yuan Tang, Ning Li, Ning-Ning Lu, Shu-Nan Qi, Yong Yang and Ye-Xiong Li*

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Background and Purpose: We investigated the locoregional effect of trastuzumab, and determined whether patients with human epidermal growth factor receptor (HER)2-positive breast cancer (BC) treated with trastuzumab could achieve comparable efficacy to that of patients with HER2-negative BC.

Materials and Methods: This was post hoc analyses of data of 793 BC patients from a randomized controlled trial comparing post-mastectomy hypofractionated radiotherapy with conventional fractionated radiotherapy. Survival rates were analyzed by the Kaplan–Meier method and compared by the log-rank test.

Results: Patients were classified into three groups: HER2-negative (HER2−; n = 547), HER2-positive with trastuzumab (HER2+ + T; n = 136), and HER2-positive without trastuzumab (HER2+ − T; n = 110). The HER2+ + T group had significantly lower locoregional recurrence (LRR, 6.0% vs. 13.9%), distant metastasis (DM, 17.4% vs. 33.8%) and higher disease-free survival (DFS, 81.2% vs. 61.9%) at 5 years than that of the HER2+ − T group (P <.05). The HER2− group had significantly lower LRR (6.8% vs. 13.9%), DM (22.4% vs. 33.8%) and higher DFS (76.1% vs. 61.9%) at 5 years than that of the HER2+ − T group (P <.05). The difference in LRR, DM and DFS at 5 years was not significant between the HER2+ + T group and HER2− group (P >.05). Different annual LRR patterns was found among groups according to HR status.
Conclusion: Trastuzumab reduces LRR in patients with locally advanced HER2-positive BC who have received post-mastectomy radiotherapy. It provides comparable DFS to that with patients with HER2-negative BC.

Keywords: breast cancer, HER2, trastuzumab, radiotherapy, prognosis

INTRODUCTION

Increased expression of human epidermal growth factor receptor (HER2), one of the most important molecular markers for breast cancer (BC), occurs in 15–25% of women with BC, and is associated with a poor prognosis (1, 2). Several randomized trials have demonstrated adjuvant use of trastuzumab (Herceptin®; Roche, Basel, Switzerland) to have a major and persistent benefit in reducing the risk of distant recurrence and death in patients with HER2-positive BC (3–5). However, the locoregional benefit of trastuzumab has not been elucidated clearly, especially in patients who have received radiotherapy (6–8). Little is known about the locoregional effect of trastuzumab in patients with locally advanced BC treated with adjuvant radiotherapy. In addition, there are limited data on outcome comparisons between patients with HER2-positive disease in the setting of trastuzumab and patients with HER2-negative disease (9, 10).

We aimed to determine whether: (i) adjuvant trastuzumab reduced locoregional recurrence (LRR) in patients with stage-II and III BC (according to AJCC 7th edition) treated with post-mastectomy radiotherapy; (ii) patients with HER2-positive BC treated with trastuzumab had comparable outcomes to those of patients with HER2-negative BC.

MATERIALS AND METHODS

Patients

This study was a post hoc analysis of data from a randomized clinical trial (NCT00793962) conducted between 2008 and 2016. The original trial recruited 820 women aged 18–75 years who had undergone mastectomy for high-risk BC with negative margins (i.e., ≥4 positive axillary lymph nodes or a primary tumor of stage T3–4) and compared post-mastectomy hypofractionated radiotherapy (HFRT, 43.5 Gy in 15 fractions over 3 weeks) with conventional fractionated radiotherapy (CFRT, 50 Gy in 25 fractions over 5 weeks). The cohort has been described in detail elsewhere (11). Patients were designated as “HER2-positive” if they demonstrated a membranous staining score of 3+ on immunohistochemical (IHC) analyses, or gene amplification on fluorescence in situ hybridization (FISH). HER2 copy number that was not amplified by FISH or read as 0–1+ by IHC was designated as “HER2-negative”. Patients who were IHC 2+ without a confirmatory FISH result were excluded from analyses (n = 17). Other clinical and histologic information of these patients was collected from case records. The final follow-up was November 2019. A total of 793 patients were included for evaluation (Figure 1).

![Trial profile](image)
Statistical Analyses
The relationship between HER2 status and outcomes was analyzed. “LRR” was defined as the first recurrence after surgery in the ipsilateral chest wall or axillary, supra-/infraclavicular, or internal mammary nodal regions regardless of the status of systemic disease. “Distant metastasis” (DM) was defined as the first recurrence after surgery in any distant site.

Overall survival (OS) was calculated from the date of the surgical procedure to the date of death due to any cause or final follow-up. Disease-free survival (DFS) was calculated from the date of surgery to date of recurrence or death, or final follow-up.

Statistical analyses were undertaken using SPSS v23.0 (IBM, Armonk, NY, USA) and R v3.5.3 (R Project for Statistical Computing, Austria, Vienna; www.r-project.org/). Categorical variables were summarized as frequencies and percentages, and were compared using the Fisher exact test or chi-square test.

The relapse rate and survival rate were calculated using the Kaplan–Meier method and compared using the log-rank test (including pairwise comparisons). The hazard rate of LRR was computed using the “muhaz” package in R. The association of potential prognostic factors with survival outcomes was tested by univariate Cox regression analysis. Factors associated with outcome in the univariate analysis (at P < .05) were entered into multivariable proportional hazards regression analysis to identify independent predictors. Statistical significance was set at P ≤ .05. Bonferroni’s correction for significance of association was applied to compensate for multiple comparisons.

RESULTS

Patient Characteristics
Table 1 shows the demographic, tumor, and treatment characteristics of the 793 patients for whom HER2 status was identified. The median age of the study cohort was 49 (range, 24–74) years. All patients underwent mastectomy and radiotherapy. All patients received a median of six (range, 4–11) cycles of chemotherapy (neoadjuvant and/or adjuvant).

According to HER2 status and trastuzumab treatment, patients were classified into three groups: HER2-negative (HER2−; n = 547, 69.0%), HER2-positive with trastuzumab treatment (HER2+ + T; n = 136, 17.1%), and HER2-positive without trastuzumab treatment (HER2+ − T; n = 110, 13.9%).

The proportion of HER2-positive patients treated with trastuzumab increased from 31.6% in 2008 to 77.8% in 2016 (Supplementary Figure 1). As shown in Table 1, the HER2+ − T group had more patients treated between 2008 and 2013 compared with that in the HER2− group and HER2+ + T group (Bonferroni-corrected P = .033 and Bonferroni-corrected P = .006, respectively).

The proportion of patients with hormonal receptor (HR)-positive

| TABLE 1 | Baseline characteristics of the 793 patients with breast cancer. |
|---|---|---|---|---|
| | Total; n (%) | HER2-negative; n (%) | HER2-positive | P |
| Treatment period (years) | | | With trastuzumab; n (%) | Without trastuzumab; n (%) |
| 2008–2013 | 566 (71.4) | 388 (70.9) | 87 (64.0) | 91 (82.7) | .005 |
| 2014–2016 | 227 (28.6) | 159 (29.1) | 49 (36.0) | 19 (17.3) | .457 |
| Age (years) | | | | | .842 |
| <40 | 139 (17.5) | 95 (17.4) | 28 (20.6) | 16 (14.5) | .669 |
| ≥40 | 654 (82.5) | 452 (82.6) | 108 (79.4) | 94 (85.5) | |
| Stage | | | | | .166 |
| II–IIIA | 498 (62.8) | 346 (63.9) | 81 (59.6) | 71 (64.5) | |
| IIIB–IIIC | 254 (33.0) | 184 (33.6) | 44 (32.4) | 38 (34.5) | |
| Lymphovascular invasion | | | | | <.001 |
| No | 531 (67.0) | 363 (66.4) | 92 (67.6) | 76 (69.1) | |
| Yes | 262 (33.0) | 184 (33.6) | 44 (32.4) | 34 (30.9) | |
| Histology grade | | | | | .224 |
| I–II | 501 (63.2) | 353 (64.5) | 86 (63.2) | 62 (56.4) | |
| III | 227 (28.6) | 145 (26.5) | 44 (32.4) | 38 (34.5) | |
| Unknown | 65 (8.2) | 49 (9.0) | 6 (4.4) | 10 (9.1) | |
| Hormonal receptor | | | | | <.001 |
| Negative | 151 (19.0) | 75 (13.7) | 47 (34.6) | 29 (26.4) | |
| Positive | 642 (81.0) | 472 (86.3) | 89 (65.4) | 81 (73.6) | |
| Neoadjuvant chemotherapy | | | | | .093 |
| No | 591 (74.5) | 417 (76.2) | 98 (72.1) | 76 (69.1) | |
| Yes | 202 (25.5) | 130 (23.8) | 38 (27.9) | 34 (30.9) | |
| Radiation fractionation | | | | | <.001 |
| HFRT | 390 (49.2) | 255 (46.6) | 78 (55.9) | 59 (53.6) | |
| CFRT | 403 (50.8) | 292 (53.4) | 60 (44.1) | 51 (46.4) | |
| Hormonal therapy | | | | | |
| No | 187 (23.6) | 101 (18.5) | 54 (39.7) | 32 (29.1) | |
| Yes | 559 (70.5) | 412 (75.9) | 79 (58.1) | 68 (61.8) | |
| Unknown | 47 (5.9) | 34 (6.2) | 3 (2.2) | 10 (9.1) | |

HER2, human epidermal growth factor receptor 2; CFRT, conventional fractionated radiotherapy; HFRT, hypofractionated radiotherapy.
disease was significantly higher in the HER2<sup>+</sup> group than that in the HER2<sup>+</sup> + T group and HER2<sup>−</sup> – T group (Bonferroni-corrected P < .001 and Bonferroni-corrected P = .003, respectively). As a result, significantly more patients in the HER2<sup>−</sup> group received hormonal therapy than patients in the HER2<sup>+</sup> + T group or HER2<sup>−</sup> – T group (Bonferroni-corrected P < .001 and Bonferroni-corrected P = .018, respectively). All other characteristics were well balanced between the three groups.

**Outcomes of the Entire Cohort**

Median follow-up was 6.8 (interquartile range: 5.0–9.1) years. LRR, DM, DFS, and OS rates at 5 years for the whole group was 7.6%, 23.1%, 75.1%, and 86.9%, respectively. There were significant differences in LRR, DM and DFS among HER2−, HER2<sup>+</sup> + T, and HER2<sup>−</sup> – T groups (P = .006, P = .001, P = .001, respectively; Figures 2A–C). However, there was no significant difference in OS among the three groups (P = .071, Figure 2D).

Further log-rank pairwise comparisons showed the HER2<sup>+</sup> + T group had significantly lower LRR, DM and higher DFS at 5 years than that in the HER2<sup>−</sup> – T group (6.0% vs. 13.9%, Bonferroni-corrected P = .048; 17.4% vs. 33.8%, Bonferroni-corrected P = .003; 81.2% vs. 61.9%, Bonferroni-corrected P = .003, respectively). The HER2<sup>+</sup> group also had significantly lower LRR, DM and higher DFS at 5 years than that in the HER2<sup>−</sup> – T group (6.8% vs. 13.9%, Bonferroni-corrected P = .009; 22.4% vs. 33.8%, Bonferroni-corrected P = .003; 76.1% vs. 61.9%, Bonferroni-corrected P = .003, respectively). However, there were no significant differences in LRR (Bonferroni-corrected P = .663), DM (Bonferroni-corrected P = .357) or DFS (Bonferroni-corrected P = .810) at 5 years between the HER2<sup>+</sup> + T group and HER2<sup>−</sup> group.

Univariate and multivariate analyses of prognostic factors for LRR, DM, DFS and OS are shown in Tables 2 and 3. In multivariate analyses, the combination of HER2 status and trastuzumab treatment was an independent prognostic factor for LRR (P = .011), DM (P = .002) and DFS (P < .001). Other independent prognostic factors were the treatment period, age, stage, neoadjuvant chemotherapy, and hormonal therapy.

**Outcomes According to HR Status**

When HR was positive, the HER2<sup>−</sup> group and HER2<sup>+</sup> + T group had significantly lower LRR (5.3% vs. 13.2%, Bonferroni-corrected P = .003; 5.7% vs. 13.2%, Bonferroni-corrected P = .044; Figure 3A), DM (21.0% vs. 31.8%, Bonferroni-corrected P = .027; 15.3% vs. 31.8%, Bonferroni-corrected P = .012; Figure 3B) and higher DFS (77.7% vs. 64.7%, Bonferroni-corrected P = .009; 83.7% vs. 64.7%, Bonferroni-corrected P = .012; Figure 3C) at 5 years than that in the HER2<sup>−</sup> – T group. There were no significant differences in LRR (Bonferroni-corrected P = .897, Figure 3A), DM (Bonferroni-corrected P = .489, Figure 3B) or DFS (Bonferroni-corrected P = .870, Figure 3C) at 5 years between the HER2<sup>−</sup> group and HER2<sup>+</sup> + T group.

When HR was negative, there were no significant differences in LRR, DM, DFS or OS among HER<sup>−</sup>, HER2<sup>+</sup> + T, or HER2<sup>−</sup> – T groups (P = .273, P = .174, P = .219, P = .508, respectively; Figures 3E–H).

**FIGURE 2** | Kaplan–Meier plots of locoregional recurrence (A), distant metastasis (B), disease-free survival (C), and overall survival (D) of patients grouped according to HER2 status and trastuzumab treatment. HER2<sup>+</sup>, HER2-negative; HER2<sup>+</sup> + T, HER2-positive with trastuzumab; HER2<sup>−</sup> – T, HER2-positive without trastuzumab.
### Annual Hazard Rate of LRR

Figure 4 shows the annual LRR patterns of the three groups in the entire cohort, HR⁺ cohort, and HR⁻ cohort. Visual inspection of the LRR hazard curves showed a difference in LRR patterns between the HER2⁺ group and HER2⁺ + T group and HER2⁻ – T group. In the entire cohort, the annual hazard rate of LRR in the HER2⁺ – T group was consistently higher than that in the HER2⁺ group or HER2⁻ + T group. The annual LRR curve of the HER2⁺ – T group displayed an obvious double-peaked pattern, with an early peak at ~2.5 years and a late peak at ~9 years. The annual LRR curve of the HER2⁻ + T group was consistently higher than the HER2⁺ + T group and HER2⁺ – T group. The annual LRR curve of the HER2⁻ – T group displayed a continuously low risk without an obvious peak (Figure 4A). The observed difference in LRR among these three groups occurred mainly during the first 5 years rather than beyond 5 years. The annual LRR rate of HER2⁺, HER2⁺ + T, and HER2⁻ – T groups was 1.4%, 1.3% and 3.0% during the first 5 years (P = .049), and 0.5%, 0.4% and 1.9% after 5 years (P = .070), respectively. The annual LRR pattern of the three groups in the HR⁺ cohort was similar to that of the entire cohort (Figure 4B). In the HR⁻ cohort, the annual LRR rate of HER2⁺, HER2⁺ + T, and HER2⁻ – T groups was 1.1%, 1.2% and 2.8% during the first 5 years (P = .042), and 0.6%, 0.6% and 2.4% after 5 years (P = .082), respectively. In the HR⁻ cohort, all three groups showed a single early LRR peak, at ~1 year for the HER2⁻ group, and at ~2 years for HER2⁺ + T and HER2⁻ – T groups (Figure 4C). The annual LRR rate of HER2⁺, HER2⁺ + T, and HER2⁻ – T groups was 3.9%, 1.4% and 3.7% during the first 5 years (P = .240), and 0.0%, 0.0% and 0.0% after 5 years, respectively.

### DISCUSSION

Previously, we demonstrated that post-mastectomy HFRT was non-inferior to CFRT in high-risk BC patients (11). The present post hoc analyses showed that: (i) trastuzumab decreased the risk of LRR and improved DFS significantly in patients with HER2-positive disease who received post-mastectomy radiotherapy (PMRT); (ii) patients with HER2-positive disease treated with trastuzumab had a comparable prognosis to that of patients with HER2-negative disease. Randomized trials have revealed survival and local-control benefits from PMRT in patients with high-risk BC (12–14). One meta-analysis concluded that PMRT reduced LRR and BC mortality, especially for patients with lymph-node involvement (15).
Therefore, patients with stage-III BC who have undergone modified mastectomy have received PMRT routinely. However, those studies were conducted in the non-trastuzumab era, and whether there is a synergistic effect between trastuzumab and PMRT is not known. As trastuzumab treatment was not covered by the national health insurance plan during the period of this study, only half of the patients with HER2-positive breast cancer received anti-HER2 therapy. It gave us an opportunity to discuss these issues. In the present study, 93.8% of patients had stage-III BC and all received PMRT. We showed that the absolute reduction in LRR from trastuzumab treatment in HER2-positive patients was 8%.

The question regarding whether trastuzumab reduces LRR risk in patients with HER2-positive disease is controversial.

| Characteristics | LRR Hazard ratio(95%CI) | P | DM Hazard ratio(95%CI) | P | DFS Hazard ratio(95%CI) | P | OS Hazard ratio(95%CI) | P |
|-----------------|-------------------------|---|------------------------|---|------------------------|---|------------------------|---|
| Treatment period (years) |              |     |                        |     |                        |     |                        |     |
| 2009–2013       | 1.00         | 1.00 | 1.00                   | 1.00 | 1.00                   | 1.00 | 1.00                   | 1.00 |
| 2014–2016       | 0.56 (0.28–1.11) | .095 | 0.67 (0.46–0.98) | .039 | 0.67 (0.47–0.97) | .033 | 0.67 (0.50–1.11) | .106 |
| Age (years)     |              |     |                        |     |                        |     |                        |     |
| <40             | 1.00         | 1.00 | 1.00                   | 1.00 | 1.00                   | 1.00 | 1.00                   | 1.00 |
| ≥40             | 0.63 (0.35–1.11) | .109 | 0.57 (0.41–0.79) | .001 | 0.58 (0.42–0.80) | .001 | 0.75 (0.50–1.11) | .151 |
| Stage           |              |     |                        |     |                        |     |                        |     |
| III–IIB         | 1.00         | 1.00 | 1.00                   | 1.00 | 1.00                   | 1.00 | 1.00                   | 1.00 |
| Lymphovascular invasion | 1.41 (0.85–2.33) | .180 | 1.97 (1.47–2.64) | <.001 | 2.00 (1.51–2.65) | <.001 | 2.27 (1.62–3.17) | <.001 |
| Hormonal receptor |              |     |                        |     |                        |     |                        |     |
| No              | 1.00         | 1.00 | 1.00                   | 1.00 | 1.00                   | 1.00 | 1.00                   | 1.00 |
| Yes             | 1.48 (0.87–2.50) | .147 | 1.17 (0.86–1.60) | .312 | 1.19 (0.88–1.61) | .245 | 1.29 (0.90–1.84) | .159 |
| Neoadjuvant chemotherapy |              |     |                        |     |                        |     |                        |     |
| No              | 1.00         | 1.00 | 1.00                   | 1.00 | 1.00                   | 1.00 | 1.00                   | 1.00 |
| Yes             | 1.41 (0.82–2.42) | .213 | 1.33 (0.97–1.84) | .078 | 1.39 (1.02–1.89) | .036 | 1.70 (1.19–2.42) | .003 |
| Hormonal therapy |              |     |                        |     |                        |     |                        |     |
| No              | 1.00         | 1.00 | 1.00                   | 1.00 | 1.00                   | 1.00 | 1.00                   | 1.00 |
| Yes             | 0.33 (0.14–0.75) | .009 | 0.62 (0.35–1.13) | .118 | 0.61 (0.35–1.07) | .087 | 0.44 (0.23–0.84) | .013 |
| HER2 and trastuzumab | 0.11 | .002 | <.001                   | 1.00 | 1.00                   | 1.00 | 1.00                   | 1.00 |
| HER2+ + T       | 0.76 (0.36–1.58) | .458 | 0.65 (0.42–1.00) | .054 | 0.68 (0.45–1.03) | .068 | 0.67 (0.41–1.06) | .105 |
| HER2− + T       | 2.18 (1.22–3.90) | .008 | 1.61 (1.12–2.32) | .010 | 1.71 (1.21–2.43) | .003 | 1.38 (0.91–2.10) | .134 |

LRR, locoregional recurrence; DM, distant metastasis; DFS, disease-free survival; OS, overall survival; HER2, human epidermal growth factor receptor 2; HER2−, HER2-negative; HER2+ + T, HER2-positive with trastuzumab; HER2− + T, HER2-positive without trastuzumab.
Perterson et al. reported similar high locoregional recurrence-free survival of 98.3% among 404 patients who received trastuzumab and 97.8% in 344 patients with T1-2N0 BC who did not receive trastuzumab (16). However, a study by Keiss and colleagues also involving patients with T1-2N0 BC showed that locoregional recurrence-free survival after breast-conserving treatment was higher among the trastuzumab-treated group (99% vs. 90%, *P* = .01) (7). Furthermore, other studies have shown that trastuzumab reduced LRR risk among HER2-positive patients with HR-positive stage-I–III BC, whereas patients with HR-negative BC had persistently increased LRR risk despite trastuzumab use (6, 17, 18). The present study showed similar findings whereby trastuzumab significantly reduced LRR risk in a HR-positive cohort rather than a HR-negative cohort, however, the sample size in the HR-negative cohort was small. The small sample size might also explain the findings that the relapse and survival outcomes were similar between triple-negative and HR-HER2+ + T groups. In HER2-positive patients with stage-I–III BC who received mastectomy, Lanning et al. found that trastuzumab did not decrease LRR risk in patients who did not receive PMRT, but it decreased LRR risk among those who received PMRT, suggesting that the greatest benefit is seen in a higher-risk subset of patients (8). That finding was confirmed by Wang et al., who found that trastuzumab reduced the 5-year LRR rate (4.9% vs. 17.9%, *P* <.05) in HER2-positive patients treated with mastectomy and PMRT (19). Taken together, data suggest that trastuzumab may play an important part in reducing LRR risk among patients with more advanced disease and those with HR-positive disease.

Analyses of hazard function defines, in much greater detail, changes in LRR risk over time and highlights when recurrence occurs rather than simply calculating the overall recurrence risk. We observed a double-peaked pattern of LRR in HER2-positive patients who did not receive trastuzumab in the HR-positive cohort, and the second peak disappeared upon trastuzumab treatment. The treatment effect of trastuzumab on LRR was not proportional over time, and occurred mainly during the first 5 years rather than beyond 5 years. Previously, it has been reported that the hazard rate for tumor relapse of estrogen receptor (ER)-positive and ER-negative tumors displays a bimodal curve with a first, dominant early peak and a second, lower later surge followed by a long-lasting "tail" (20). A double-peaked pattern of relapse or death has been observed in BC patients regardless of ER status or HER2 status in the absence of trastuzumab (21). Ribelles and colleagues also observed this double-peaked pattern of relapse or death in a Luminal B and HER2-positive group (88% treated without trastuzumab), whereas a single early peak was noted in a triple-negative group (22). However, reports on LRR patterns are limited. The present study is the first to show different annual LRR patterns among groups stratified by trastuzumab treatment and according to HR status. In contrast to our findings that trastuzumab did not significantly reduce the risk of LRR beyond 5 years, a combined analysis for relapse or death by Chumsri and coworkers showed that the benefit of adjuvant trastuzumab therapy was seen in years 0 to 5 (hazard ratio, 0.42; *P* = .001) and years 5 to 10 (hazard ratio, 0.69; *P* = .03) (23). This difference might be explained by the different endpoints used in our study, or...
inadequate samples that prevented achievement of a significant difference in comparison beyond 5 years. Although little clinical data exist on the interaction of HR status and HER2 status on locoregional outcomes in the trastuzumab era, these findings indicated different surveillance strategies for different groups.

Randomized studies have established that trastuzumab improves the survival rates of patients with HER2-positive tumors (3–5, 23), whereas studies are limited for comparing the outcome of HER2-positive patients taking trastuzumab with that of HER2-negative patients. We found that HER2-positive patients taking trastuzumab had comparable DFS with that of HER2-negative patients. This finding has been corroborated by other studies. Fokter et al. reported no significant difference in DFS between trastuzumab-treated HER2-positive patients and HER2-negative patients (9). Qin et al. found that the DFS difference at 5 years between HER2-negative patients and HER2-positive patients receiving trastuzumab was not significant (71.7% vs. 77.8%, \( P = .503 \)) (10). Some studies on locally advanced BC or metastatic BC have shown that trastuzumab-treated HER2-positive patients have better event-free survival or OS than that in patients with HER2-negative BC (24, 25). The negative prognostic effect of HER2-positivity observed before trastuzumab treatment became available might disappear completely in the era of routine administration of trastuzumab. Therefore, the prognostic importance of HER2 status must be considered in the context of anti-HER2 treatment. In the recent eighth edition of the American Joint Committee on Cancer (AJCC) staging system for BC, the prognostic-stage groups showed that patients with HER2-positive tumors tended to be grouped into a lower stage than patients with HER2-negative tumors provided that other staging factors were identical because most of the patients used to generate the eighth edition of the AJCC staging system in the initial models received trastuzumab (26). For example, for a patient with T3N2M0, grade 3, ER-positive, and PR-positive BC, she was grouped into IIA if HER2 was positive, and IIB if HER2 was negative.

Our study had three main limitations. First, thanks to developments in diagnostic and therapeutic strategies, treatment guidelines for patients with BC have changed, and our study population may not reflect the outcomes for patients being treated currently. This study initiated originally from 2008, so we found the treatment period to be an independent predictor for DM and DFS. Nevertheless, the combination of HER2 status and trastuzumab treatment was demonstrated to be an independent predictor for LRR, DM, and DFS after adjustment for the treatment period. Second, because of the limited follow-up time, the findings on hazard rates over time warrant further validation. Third, this study was an unplanned post hoc analysis, patients taking and not taking trastuzumab were not assigned randomly, so a selection bias was unavoidable. We attempted to eliminate the influence of confounding factors in the multivariate analysis by including all other known prognostic factors. Nevertheless, this study is the first to assess the locoregional effect of trastuzumab in patients with locally advanced BC treated with adjuvant radiotherapy, and the findings on the LRR patterns over time merit further investigation.

CONCLUSIONS

Trastuzumab reduces the risk of LRR in patients with locally advanced HER2-positive BC who have received PMRT. It provides comparable DFS in patients with HER2-positive disease to those with HER2-negative disease.

DATA AVAILABILITY STATEMENT

All datasets presented in this study are included in the article/Supplementary Material.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institutional Review Board of Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

G-YS and HJ: Formal analysis, investigation, data collection, methodology, and writing of first draft. Y-WS, JJ, HF, Y-PL, HR, YuT, BC, YuaT, NL, N-NL, S-NQ, YY: Patient care and review and editing of the manuscript. X-RZ, Y-CS, S-YC, Z-BY: Data collection and review of the original draft and editing. S-LW, Y-XL: Formal analysis and data collection, validation, statistics guidance, and project administration, patient care, and writing and editing of the first draft of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grants from Beijing Marathon of Hope, Cancer Foundation of China (LC2012A11) and National Natural Science Foundation of China (81972860).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.605750/full#supplementary-material

Supplementary Figure 1 | The trends of the proportion of HER2-positive patients treated with trastuzumab over the study period.
REFERENCES

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:70–12. doi: 10.1126/science.2470152

2. Wang SL, Li XQ, Song YW, Wang WH, Jin J, Liu YP, et al. Triple-negative or HER-2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy. Int J Radiat Oncol Biol Phys (2011) 80:1095–101. doi: 10.1016/j.ijrobp.2010.03.038

3. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr., et al. Adjuvant trastuzumab plus chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol (2014) 32:3744–52. doi: 10.1200/JCO.2014.55.5730

4. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 365:1273–83. doi: 10.1056/NEJMoa101388

5. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years’ follow-up of trastuzumab adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERcepTin Adjuvant (HERA) trial. Lancet (2017) 389:1195–205. doi: 10.1016/s0140-6736(16)32616-2

6. Cao L, Cai G, Xu F, Yang ZZ, Yu XL, Ma JL, et al. Trastuzumab improves survival from NSABP B-31 and NCCTG N9831. Ann Surg Oncol (2015) 22:2517–35. doi: 10.1245/s10434-014-4321-2

7. Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, et al. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancer (2012) 118:1982–8. doi: 10.1002/cncr.26484

8. Lanning RM, Morrow M, Riaz N, McArthur HL, Dang C, Moo TA, et al. The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy. Ann Surg Oncol (2015) 22:2517–25. doi: 10.1245/s10434-014-4321-2

9. Fotker Donvnik N, Donvnik A, Cas Sikosek N, Ravnik M, Arko D, Takac I. Prognostic Role of HER2 Status and Adjuvant Trastuzumab Treatment in Lymph Node-Negative Breast Cancer Patients - a Retrospective Single Center Analysis. Breast Care (Basel) (2016) 11:406–10. doi: 10.1159/000454490

10. Qin T, Yuan Z, Peng R, Bai B, Shi Y, Teng X, et al. HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients. Onco Targets Ther (2013) 6:341–7. doi: 10.2147/OTT.S40851

11. Wang S-L, Fang H, Song Y-W, Wang W-H, Hu C, Liu Y-P, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol (2019) 20:352–60. doi: 10.1016/s1470-2045(18)30813-1

12. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersen M, Bach F, et al. Postoperative radiotherapy in high-risk premastectomy women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med (1997) 337:949–55. doi: 10.1056/NEJM199702233371401

13. Overgaard M, Jensen M-B, Overgaard J, Hansen PS, Rose C, Andersen M, et al. Postoperative radiotherapy in high-risk postmastectomy breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet (1999) 353:1641–8. doi: 10.1016/s0140-6736(98)02921-0

14. Ragaz J, Jackson SM, Le N, Plenderleith I, Spinelli JJ, Rosco VE, et al. Adjuvant radiotherapy and chemotherapy in node-positive premastectomy women with breast cancer. N Engl J Med (1997) 337:956–62. doi: 10.1056/NEJM199702233371402

15. Ebetok. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet (2014) 383:2127–35. doi: 10.1016/s0140-6736(14)60488-8

16. Peterson DJ, Truong PT, Sadek BT, Alexander CS, Wiskayk B, Shenouda M, et al. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer. Ann Surg Oncol (2014) 21(11):3490–6. doi: 10.1245/s10434-014-3767-6

17. Kim MM, Dawood S, Allen P, Sahin AA, Woodward WA, Smith BD, et al. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer (2012) 118:4936–43. doi: 10.1002/cncr.27590

18. McGuire A, Kalinina O, Holian E, Curran C, Malone CA, MaLaughlin R, et al. Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab. Breast Cancer Res Treat (2017) 164:221–9. doi: 10.1007/s10549-017-4225-5

19. Wang J, Luo J, Jin K, Wang X, Yang Z, Ma J, et al. Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients. Cancer Med (2020) 9:2427–34. doi: 10.1002/cam4.2904

20. Demicheli R, Biganzoli E, Arolindo I, Boracchi P, Coradini D, Greco M, et al. Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence. Cancer Sci (2010) 101:826–30. doi: 10.1111/j.1349-7006.2009.01472.x

21. Yin W, Di G, Zhou L, Lu J, Liu G, Wu J, et al. Time-varying pattern of recurrence risk for Chinese breast cancer patients. Breast Cancer Res Treat (2009) 114:527–35. doi: 10.1007/s10549-008-0022-5

22. Ribelles N, Perez-Velazquez M, Perez JM, Pajares B, Vicioso I, Jimenez B, et al. Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res CR (2013) 15:R98. doi: 10.1186/bcr3559

23. Chwurski S, Li Z, Serie DJ, Mashadi-Hosseini A, Colon-Otero G, Song N, et al. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. J Clin Oncol (2019) 37:3425–35. doi: 10.1200/JCO.2019.004434

24. Gianni L, Eiermann W, Semiglavoz V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet (2010) 375:377–84. doi: 10.1016/S0140-6736(09)61964-4

25. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-basedreview. J Clin Oncol (2010) 28:92–8. doi: 10.1200/JCO.2008.19.9844

26. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. AJCC Cancer Staging Manual. New York: Springer (2017). doi: 10.1007/978-3-319-40618-3

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Sun, Jing, Wang, Song, Jin, Fang, Liu, Ren, Tang, Zhao, Song, Chen, Yang, Chen, Li, Lu, Qi, Yang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.